Tags

Type your tag names separated by a space and hit enter

Prognostic value of NDRG1 and SPARC protein expression in breast cancer patients.
Breast Cancer Res Treat. 2011 Feb; 126(1):1-14.BC

Abstract

An increasing number of studies have shown altered expression of secreted protein acidic and rich in cysteine (SPARC) and N-myc down-regulated gene (NDRG1) in several malignancies, including breast carcinoma; however, the role of these potential biomarkers in tumor development and progression is controversial. In this study, NDRG1 and SPARC protein expression was evaluated by immunohistochemistry on tissue microarrays containing breast tumor specimens from patients with 10 years of follow-up. NDRG1 and SPARC protein expression was determined in 596 patients along with other prognostic markers, such as ER, PR, and HER2. The status of NDRG1 and SPARC protein expression was correlated with prognostic variables and patient clinical outcome. Immunostaining revealed that 272 of the 596 cases (45.6%) were positive for NDRG1 and 431 (72.3%) were positive for SPARC. Statistically significant differences were found between the presence of SPARC and NDRG1 protein expression and standard clinicopathological variables. Kaplan-Meier analysis showed that NDRG1 positivity was directly associated with shorter disease-free survival (DFS, P < 0.001) and overall survival (OS, P < 0.001). In contrast, patients expressing low levels of SPARC protein had worse DFS (P = 0.001) and OS (P = 0.001) compared to those expressing high levels. Combined analysis of the two markers indicated that DFS (P < 0.001) and OS rates (P < 0.001) were lowest for patients with NDRG1-positive and SPARC-negative tumors. Furthermore, NDRG1 over-expression and SPARC down-regulation correlated with poor prognosis in patients with luminal A or triple-negative subtype breast cancer. On multivariate analysis using a Cox proportional hazards model, NDRG1 and SPARC protein expression were independent prognostic factors for both DFS and OS of breast cancer patients. These data indicate that NDRG1 over-expression and SPARC down-regulation could play important roles in breast cancer progression and serve as useful biomarkers to better define breast cancer prognosis.

Authors+Show Affiliations

Disciplina de Oncologia, Departamento de Radiologia, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil. nagai@usp.brNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

20369286

Citation

Nagai, Maria Aparecida, et al. "Prognostic Value of NDRG1 and SPARC Protein Expression in Breast Cancer Patients." Breast Cancer Research and Treatment, vol. 126, no. 1, 2011, pp. 1-14.
Nagai MA, Gerhard R, Fregnani JH, et al. Prognostic value of NDRG1 and SPARC protein expression in breast cancer patients. Breast Cancer Res Treat. 2011;126(1):1-14.
Nagai, M. A., Gerhard, R., Fregnani, J. H., Nonogaki, S., Rierger, R. B., Netto, M. M., & Soares, F. A. (2011). Prognostic value of NDRG1 and SPARC protein expression in breast cancer patients. Breast Cancer Research and Treatment, 126(1), 1-14. https://doi.org/10.1007/s10549-010-0867-2
Nagai MA, et al. Prognostic Value of NDRG1 and SPARC Protein Expression in Breast Cancer Patients. Breast Cancer Res Treat. 2011;126(1):1-14. PubMed PMID: 20369286.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Prognostic value of NDRG1 and SPARC protein expression in breast cancer patients. AU - Nagai,Maria Aparecida, AU - Gerhard,Renê, AU - Fregnani,José Humberto T G, AU - Nonogaki,Suely, AU - Rierger,Regina Barbosa, AU - Netto,Mário Mourão, AU - Soares,Fernando A, Y1 - 2010/04/06/ PY - 2010/02/25/received PY - 2010/03/20/accepted PY - 2010/4/7/entrez PY - 2010/4/7/pubmed PY - 2011/5/6/medline SP - 1 EP - 14 JF - Breast cancer research and treatment JO - Breast Cancer Res Treat VL - 126 IS - 1 N2 - An increasing number of studies have shown altered expression of secreted protein acidic and rich in cysteine (SPARC) and N-myc down-regulated gene (NDRG1) in several malignancies, including breast carcinoma; however, the role of these potential biomarkers in tumor development and progression is controversial. In this study, NDRG1 and SPARC protein expression was evaluated by immunohistochemistry on tissue microarrays containing breast tumor specimens from patients with 10 years of follow-up. NDRG1 and SPARC protein expression was determined in 596 patients along with other prognostic markers, such as ER, PR, and HER2. The status of NDRG1 and SPARC protein expression was correlated with prognostic variables and patient clinical outcome. Immunostaining revealed that 272 of the 596 cases (45.6%) were positive for NDRG1 and 431 (72.3%) were positive for SPARC. Statistically significant differences were found between the presence of SPARC and NDRG1 protein expression and standard clinicopathological variables. Kaplan-Meier analysis showed that NDRG1 positivity was directly associated with shorter disease-free survival (DFS, P < 0.001) and overall survival (OS, P < 0.001). In contrast, patients expressing low levels of SPARC protein had worse DFS (P = 0.001) and OS (P = 0.001) compared to those expressing high levels. Combined analysis of the two markers indicated that DFS (P < 0.001) and OS rates (P < 0.001) were lowest for patients with NDRG1-positive and SPARC-negative tumors. Furthermore, NDRG1 over-expression and SPARC down-regulation correlated with poor prognosis in patients with luminal A or triple-negative subtype breast cancer. On multivariate analysis using a Cox proportional hazards model, NDRG1 and SPARC protein expression were independent prognostic factors for both DFS and OS of breast cancer patients. These data indicate that NDRG1 over-expression and SPARC down-regulation could play important roles in breast cancer progression and serve as useful biomarkers to better define breast cancer prognosis. SN - 1573-7217 UR - https://www.unboundmedicine.com/medline/citation/20369286/Prognostic_value_of_NDRG1_and_SPARC_protein_expression_in_breast_cancer_patients_ L2 - https://doi.org/10.1007/s10549-010-0867-2 DB - PRIME DP - Unbound Medicine ER -